These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2168 related articles for article (PubMed ID: 20609178)

  • 1. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC
    Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
    Locatelli F; Covic A; Macdougall IC; Wiecek A;
    J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
    Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M; Hojs N; Premru V
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A; Covic A; Locatelli F; Macdougall IC;
    Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia management and treatment response in patients on hemodialysis: the MAR study.
    Portolés J; López-Gómez JM; Aljama P
    J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 109.